Site is Being Upgraded

Life-extension therapy: Lansoprazole, a drug used in the treatment of stomach and duodenal ulcers,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 6/February/2017, 6.30 pm

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: D-3-Hydroxybutyrate (3DHB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 5/February/2018, 11.06 pm
February 5, 2018
Molecular therapy for TIIDM and obesity-associated metabolic deficits: D-3-hydroxybutyrate (D3HB)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 6/February/2018, 6.45 am
February 6, 2018
Show all

What they say?

A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published, in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 ), by Prof Dominic J. Withers, Dr. Selman C and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports, for the first time, that: Life-extension therapy: Lansoprazole, a drug used in the treatment of stomach and duodenal ulcers,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span


Research findings to Therapeutic opportunity: 

Lansoprazole is used in the treatment of the treatment of stomach and duodenal ulcers .  This study suggests, for the first time, that Lansoprazoleby  increasing  the expression of its target gene, it may suppress Ribosomal protein S6 kinase 1 (p70S6 Kinase) expression. Thereby, it may promote: (1) resistance to bone, immune, and motor dysfunction; (2) insulin sensitivity; and (3) longevity (fig. 1).   

Fig 1. Lansoprazole may function as a longevity promoter by suppressing the expression of p70 S6 Kinase

Figure 2. The chemical structure of Lansoprazole

[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing “Lansoprazole or its analogues,  either alone or or in combination with any of the known longevity-promoting compound(s)” may be used to extend the lifespan of an individual (fig. 1).


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed Information: How Prednisolone decreases the expression of p70 S6 Kinase and promotes mammalian life span?

# Research cooperation

Amount: $100 #


References:

CitationBoominathan, L.,  Life-extension therapy: Lansoprazole, a drug used in the treatment of stomach and duodenal ulcers,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 6/February/2017, 6.32 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.